ViRexx is a Canadian biotechnology company focused on the research and development of targeted therapeutic products for people suffering from chronic viral infections or cancers. ViRexx’s proprietary Chimigen™ Vaccine Platform is being used to develop vaccines for the treatment of patients with chronic hepatitis B and C virus infections. In addition, the platform is used to develop biodefense vaccines and pandemic influenza vaccines and targeted bionanoparticles. The Company also has a two distinct programs: T-ACT™ embolotherapeutic agents, and AIT® immunotherapeutic drug candidates. Both technologies address significant unmet medical needs in the treatment of cancer and solid tumours.
Virexx is based in Edmonton Alberta, and trades on the Toronto Stock Exchange under the symbol VIR and the American Stock Exchange under the symbol REX… more